Please login to the form below
RSV
This page shows the latest RSV news and features for those working in and with pharma, biotech and healthcare.
GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
GSK also announced positive phase 3 results last month for its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and older. ... According to a statement from GSK, the company remains ‘on track’ to supply the vaccine
Latest news
-
Pfizer’s RSV vaccine candidate for older adults backed by FDA Advisory Committee
RSV infections in older adults account for 60, 000 to 160, 000 hospitalisations each year in the US. ... lower respiratory tract disease caused by RSV in those aged 60 years and older.
-
FDA authorises first at-home COVID-19 and flu test for emergency use
Citing the impact of COVID-19, flu and RSV, the FDA stated it ‘recognises the benefits that home testing can provide’ and will continue to work to increase the number of
-
AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants
RSV is a contagious virus and the most common cause of LRTIs, including bronchiolitis and pneumonia, in infants. ... Beyfortus has already been approved in the EU and UK as the first and only approved RSV prevention designed for use in all infants.
-
Pfizer’s maternal RSV vaccine candidate accepted for FDA priority review
There is currently no US-approved vaccine for RSV, a contagious virus characterised by several mild, cold-like symptoms. ... of this infectious disease that, although well known, has been particularly evident throughout this RSV season.”.
-
Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households
to further study the ways it may benefit patients with other infectious diseases, such as RSV,” he said.
More from news
Approximately 11 fully matching, plus 63 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
challenge study, in this case respiratory syncytial virus (RSV).
-
Deal Watch October 2018
The previous licensing deal was for exclusive global rights to the phase 1‐ready RSV compound, AK0529 which is now in a phase 2 study.
-
Deal Watch table for September 2014
Alios / J&J. Company acquisition. Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV.
-
Pharma deals during September 2014
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
-
Deal Watch table for June 2013
175. MicroDose Therapeutx / Teva. Acquisition. Acquisition of inhalation technology including MDT-637 for RSV (phase II).
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
development and commercialisation of the Mimopath platform including our RSV vaccine candidate.". ... During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
